Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety, tolerability and effectiveness of olesoxime in spinal muscular atrophy
2015-001589-25Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olesoxime in spinal muscular atrophy (SMA), sponsored by Roche. Primary endpoint: Incidence of adverse events. Started Aug 2015; status: completed.
02
Drugs
olesoxime
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2015-001589-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001589-25.